- Title
- 178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study
- Creators
- K. Fujiwara - Saitama Medical UniversityR. Kristeleit - Guy's and St Thomas' NHS Foundation TrustS. Ghamande - Augusta UniversityM-C. Lim - Swedish InstituteC. Parkinson - Addenbrooke's HospitalM. Morgan - University of Pennsylvania Health SystemM.K. Wilson - Auckland City HospitalA. Oaknin - Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology, Hospital Universitario Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SpainJ. Buscema - Arizona OncologyP. Bessette - Department of Obstetrics and Gynecology, University of Sherbrooke, Sherbrooke, QC, CanadaD. Lorusso - Università Cattolica del Sacro CuoreF. Ueland - University of KentuckyT. Safra - FacultyJ.N. Barlin - Division Of Gynecologic Oncology, Women’s Cancer Care Associates, Albany Medical College, Albany, NY, USAF. Marmé - Department of Obstetrics and Gynecology, University Hospital Mannheim, Mannheim, GermanyT.J. Herzog - University of CincinnatiI.A. McNeish - Imperial College LondonS. Goble - Clovis OncologyS. Hume - Clovis OncologyB.J. Monk - Creighton University
- Publication Details
- Annals of oncology, Vol.33, pp.S1505-S1506
- Publisher
- Elsevier Ltd
- Identifiers
- 991005969147302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study
Annals of oncology, Vol.33, pp.S1505-S1506
11/2022
Metrics
4 Record Views